BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of a metabolic syndrome. To date, liver biopsy has been the gold standard used to differentiate between simple steatosis and steatohepatitis/fibrosis. Our aim was to compare the relevance of serum non-invasive parameters and scoring systems in the staging of liver fibrosis and non-alcoholic steatohepatitis (NASH) in patients with NAFLD. METHODS AND FINDINGS: A total of 112 consecutive patients diagnosed with NAFLD were included. A liver biopsy was performed on 56 patients. The Kleiner score was used for the staging and grading of the histology. Non-invasive parameters for fibrosis (hyaluronic acid; AST/ALT; fibrosis scoring indexes OELF, ELF, BARD score, APRI, NAFLD fibrosis score); and inflammation (M30 and M65 cytokeratin-18 fragments) were measured and calculated. The same analyses were performed in 56 patients diagnosed with NAFLD, who were not indicated for liver biopsy. Based on the liver histology, NASH was diagnosed in 38 patients; simple steatosis in 18 patients. A cut-off value of 750 U/L of serum M65 discriminated patients with and without NASH with a 80% sensitivity and 82% specificity (95% CI:57-95). Fibrosis stage F0-F2 was present in 39 patients; F3-F4 in 17 patients. Serum concentrations of hyaluronic acid were higher in patients with advanced fibrosis (p<0.01); a cut-off value of 25 µg/l discriminated patients with F3-F4 with a 90% sensitivity and 84% specificity from those with F0-F2 (95% CI:59-99). When applying the non-invasive criteria to those patients without a liver biopsy, NASH could only be diagnosed in 16%; however, advanced fibrosis could be diagnosed in 35% of them. CONCLUSIONS: In patients with NAFLD, non-invasive serum parameters with a high accuracy can differentiate those patients with NASH and/or advanced fibrosis from those with simple steatosis. A substantial portion of those patients not indicated for liver biopsy might have undiagnosed advanced fibrosis.

Charles University Prague 1st Faculty of Medicine 3rd Department of Internal Medicine Prague Czech Republic

Charles University Prague 1st Faculty of Medicine 4th Department of Internal Medicine Prague Czech Republic

Charles University Prague 1st Faculty of Medicine 4th Department of Internal Medicine Prague Czech Republic; Charles University Prague 1st Faculty of Medicine Institute of Medical Biochemistry and Laboratory Diagnostics Prague Czech Republic

Charles University Prague 1st Faculty of Medicine Department of Pathology Prague Czech Republic

Charles University Prague 1st Faculty of Medicine Institute of Medical Biochemistry and Laboratory Diagnostics Prague Czech Republic

Zobrazit více v PubMed

Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917–923. PubMed

Bravo AA, Sheth SG, Chopra S (2001) Liver biopsy. N Engl J Med 344: 495–500. PubMed

Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, et al. (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128: 1898–1906. PubMed

Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, et al. (2006) Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 44: 874–880. PubMed

Machado MV, Cortez-Pinto H (2013) Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 58: 1007–1019. PubMed

Shimada M, Hashimoto E, Kaneda H, Noguchi S, Hayashi N (2002) Nonalcoholic steatohepatitis: risk factors for liver fibrosis. Hepatol Res 24: 429–438. PubMed

Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA (2008) Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57: 1441–1447. PubMed

Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, et al. (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45: 846–854. PubMed

Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, et al. (2007) FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 46: 32–36. PubMed

Suzuki A, Angulo P, Lymp J, Li D, Satomura S, et al. (2005) Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 25: 779–786. PubMed

Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, et al. (2004) Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127: 1704–1713. PubMed

Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, et al. (2008) Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47: 455–460. PubMed

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005–2023. PubMed

Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, et al. (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 38: 518–526. PubMed

Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, et al. (2009) Liver biopsy. Hepatology 49: 1017–1044. PubMed

Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, et al. (2007) Transjugular liver biopsy–indications, adequacy, quality of specimens, and complications–a systematic review. J Hepatol 47: 284–294. PubMed

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313–1321. PubMed

Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94: 2467–2474. PubMed

Brunt EM (2004) Nonalcoholic steatohepatitis. Semin Liver Dis 24: 3–20. PubMed

Sumida Y, Nakajima A, Itoh Y (2014) Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 20: 475–485. PubMed PMC

Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, et al. (2013) The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol 59: 236–242. PubMed

Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, et al. (2009) Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 136: 160–167. PubMed

Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, et al. (2011) Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 54: 1082–1090. PubMed PMC

Schuppan D, Schattenberg JM (2013) Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 28 Suppl 1 68–76. PubMed

Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, et al. (2003) Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125: 437–443. PubMed

Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, et al. (2007) Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 13: 837–844. PubMed PMC

Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, et al. (2006) In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44: 27–33. PubMed

Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, et al. (2009) Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50: 1072–1078. PubMed PMC

Joka D, Wahl K, Moeller S, Schlue J, Vaske B, et al. (2012) Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 55: 455–464. PubMed

Chen J, Zhu Y, Zheng Q, Jiang J (2013) Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis. Hepatol Res. PubMed

Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, et al. (2014) Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease–the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 39: 254–269. PubMed

Lebensztejn DM, Wierzbicka A, Socha P, Pronicki M, Skiba E, et al. (2011) Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. Acta Biochim Pol 58: 563–566. PubMed

Sowa JP, Heider D, Bechmann LP, Gerken G, Hoffmann D, et al. (2013) Novel algorithm for non-invasive assessment of fibrosis in NAFLD. PLoS One 8: e62439. PubMed PMC

Clinically silent LINE 1 insertion in the PNPLA3 gene may impede genotyping of the p.I148M variant